What is Sophion Bioscience?
Sophion Bioscience is a premier provider of automated patch clamp solutions, serving as a cornerstone for ion channel research and drug discovery. The company's portfolio, which includes the QPatch and Qube 384 platforms, enables researchers to conduct high-precision electrophysiological measurements with unprecedented throughput. By integrating advanced cell handling and temperature control modules, Sophion supports a diverse clientele ranging from global pharmaceutical giants and contract research organizations to academic institutions and the agrochemical industry. Their commitment to technical excellence and research efficiency has established them as a vital partner in the development of novel therapeutics and safety pharmacology assessments.
How much funding has Sophion Bioscience raised?
Sophion Bioscience has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Sophion Bioscience
PPP
Public-Private Partnership
What's next for Sophion Bioscience?
With the recent influx of capital, Sophion Bioscience is poised to transition into a new phase of growth, focusing on the expansion of its automated screening capabilities and the refinement of its service-oriented technology access programs. The strategic deployment of these funds will likely prioritize the enhancement of R&D pipelines to meet the increasing demand for high-fidelity data in drug discovery. As the industry shifts toward more complex, high-throughput screening requirements, Sophion is strategically aligned to capture additional market share by leveraging its established reputation for reliability and technical innovation in the ion channel research domain.
See full Sophion Bioscience company page
